PUBLICATION
AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis
- Authors
- Zhu, L., Fang, L.
- ID
- ZDB-PUB-170214-68
- Date
- 2015
- Source
- Methodist DeBakey cardiovascular journal 11: 160-5 (Review)
- Registered Authors
- Fang, Longhou
- Keywords
- AIBP, angiogenesis, apoA-I binding protein, cholesterol efflux, lymphangiogenesis, reverse cholesterol transport
- MeSH Terms
-
- Animals
- Arteries/drug effects
- Arteries/metabolism*
- Arteries/pathology
- Arteries/physiopathology
- Atherosclerosis/drug therapy
- Atherosclerosis/metabolism*
- Atherosclerosis/pathology
- Atherosclerosis/physiopathology
- Carrier Proteins/metabolism*
- Carrier Proteins/therapeutic use
- Cholesterol, HDL/metabolism*
- Humans
- Models, Animal
- Neovascularization, Pathologic*
- Signal Transduction
- Vascular Endothelial Growth Factor Receptor-2/metabolism
- Zebrafish
- PubMed
- 26634023 Full text @ Methodist Debakey Cardiovasc J
Citation
Zhu, L., Fang, L. (2015) AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis. Methodist DeBakey cardiovascular journal. 11:160-5.
Abstract
Cardiovascular disease, which is often driven by hypercholesterolemia and subsequent coronary atherosclerosis, is the number-one cause of morbidity and mortality in the United States. Based on long-term epidemiological studies, high-density lipoprotein cholesterol (HDL-C) levels are inversely correlated with risk for coronary artery disease (CAD). HDL-mediated reverse cholesterol transport (RCT) is responsible for cholesterol removal from the peripheral tissues and return to the liver for final elimination.1 In atherosclerosis, intraplaque angiogenesis promotes plaque growth and increases plaque vulnerability. Conceivably, the acceleration of RCT and disruption of intraplaque angiogenesis would inhibit atherosclerosis and reduce CAD. We have identified a protein called apoA-I binding protein (AIBP) that augments HDL functionality by accelerating cholesterol efflux. Furthermore, AIBP inhibits vascular endothelial growth factor receptor 2 activation in endothelial cells and limits angiogenesis.2 The following discusses the prospect of using AIBP as a novel therapeutic approach for the treatment of CAD.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping